Cancer Epidemiology
Volume 34, Issue 3 , Pages 238-243 , June 2010

Recent trends in breast cancer incidence rates in the Loire-Atlantique, France: A decline since 2003

  • A.M. Fontenoy

      Affiliations

    • Registre des cancers de Loire-Atlantique et de Vendée, 50 route de Saint-Sébastien, 44093 Nantes Cedex 1, France
    • ,
  • C. Leux

      Affiliations

    • Registre des cancers de Loire-Atlantique et de Vendée, 50 route de Saint-Sébastien, 44093 Nantes Cedex 1, France
    • ,
  • S. Delacour-Billon

      Affiliations

    • Registre des cancers de Loire-Atlantique et de Vendée, 50 route de Saint-Sébastien, 44093 Nantes Cedex 1, France
    • ,
  • C. Allioux

      Affiliations

    • Structure de gestion du dépistage organisé en Loire-Atlantique, Cancer Atlantique Prévention (CAP) Santé Plus 44, Nantes, France
    • ,
  • J.S. Frenel

      Affiliations

    • Service d’oncologie médicale, Centre René Gauducheau, Saint Herblain, France
    • ,
  • M. Campone

      Affiliations

    • Service d’oncologie médicale, Centre René Gauducheau, Saint Herblain, France
    • ,
  • F. Molinié

      Affiliations

    • Registre des cancers de Loire-Atlantique et de Vendée, 50 route de Saint-Sébastien, 44093 Nantes Cedex 1, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 2 40 84 69 81; fax: +33 2 40 84 69 82.

,Accepted 15 March 2010.

References 

  1. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356:1670–1674
  2. Johnston M. Breast cancer drop linked to fall in use of HRT. http://www.nzherald.co.nz/health/news/article.cfm?c_id=204&objectid=10416198; 2006.
  3. Canfell K, Banks E, Moa AM, Beral V. Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust. 2008;188:641–644
  4. Vankrunkelsven P, Kellen E, Lousbergh D, Cloes E, Op de Beeck L, Faes C, et al. Reduction in hormone replacement therapy use and declining breast cancer incidence in the Belgian province of Limburg. Breast Cancer Res Treat. 2009;118:425–432
  5. Katalinic A, Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat. 2008;107:427–430
  6. Kerlikowske K, Miglioretti DL, Buist DS, Walker R, Carney PA. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst. 2007;99:1335–1339
  7. Li CI, Daling JR. Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004. Cancer Epidemiol Biomarkers Prev. 2007;16:2773–2780
  8. Zanetti R, Ponti A, Rosso S, Ricceri F, Pitarella S, Segnan N. The beginning of a decline in breast cancer incidence in Italy?. Tumori. 2008;94:293–296
  9. Allemand H, Seradour B, Weill A, Ricordeau P. Decline in breast cancer incidence in 2005 and 2006 in France: a paradoxical trend. Bull Cancer. 2008;95:11–15
  10. Séradour B, Allemand H, Weill A, Ricordeau P. Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from 2000 to 2006. Bull Cancer. 2009;96:E1–E6
  11. IARC . Standards and guidelines for cancer registration in Europe: the ENCR recommendations. vol. 1. Lyon: IARC; 2008;
  12. Ferlay J, Burkhard C, Whelan S, Parkin DM. Check and conversion programs for cancer registries (IARC/IACR Tools for Cancer Registries). IARC Technical Report No. 42, Lyon; 2005.
  13. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0; 2008.
  14. Belot A, Grosclaude P, Bossard N, Jougla E, Benhamou E, Delafosse P, et al. Cancer incidence and mortality in France over the period 1980–2005. Rev Epidemiol Sante Publique. 2008;56:159–175
  15. Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 2008;44:1345–1389
  16. Hery C, Ferlay J, Boniol M, Autier P. Changes in breast cancer incidence and mortality in middle-aged and elderly women in 28 countries with Caucasian majority populations. Ann Oncol. 2008;19:1009–1018
  17. Bouchardy C, Usel M, Verkooijen HM, Fioretta G, Benhamou S, Neyroud-Caspar I, et al. Changing pattern of age-specific breast cancer incidence in the Swiss canton of Geneva. Breast Cancer Res Treat. 2009;120:519–523
  18. Soerjomataram I, Coebergh JW, Louwman MW, Visser O, van Leeuwen FE. Does the decrease in hormone replacement therapy also affect breast cancer risk in the Netherlands?. J Clin Oncol. 2007;25:5038–5039[author reply 5039–40]
  19. Kumle M. Declining breast cancer incidence and decreased HRT use. Lancet. 2008;372:608–610
  20. Zahl PH, Maehlen J. A decline in breast-cancer incidence. N Engl J Med. 2007;357:510–511[author reply 513]
  21. Glass AG, Lacey JV, Carreon JD, Hoover RN. Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst. 2007;99:1152–1161
  22. Cap santé plus. Rapport d’activité de l’année 2008; 2009.
  23. Clarke CA, Glaser SL. Declines in breast cancer after the WHI: apparent impact of hormone therapy. Cancer Causes Control. 2007;18:847–852
  24. Hausauer AK, Keegan TH, Chang ET, Clarke CA. Recent breast cancer trends among Asian/Pacific Islander, Hispanic, and African-American women in the US: changes by tumor subtype. Breast Cancer Res. 2007;9:R90
  25. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004;291:47–53
  26. Parkin DM. Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy?. Eur J Cancer. 2009;45:1649–1653
  27. Dietel M, Lewis MA, Shapiro S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod. 2005;20:2052–2060
  28. French Health Products Safety Agency (Afssaps). Hormone replacement therapy. http://www.afssaps.fr/Infos-de-securite/Lettres-aux-professionnels-de-sante/Traitement-hormonal-substitutif-de-la-menopause-THS; 2003.
  29. French Health Products Safety Agency (Afssaps). Report on hormonal replacement therapy for menopause. http://www.afssaps.fr/Infos-de-securite/Communiques-de-presse/Donnees-francaises-sur-le-traitement-hormonal-substitutif-de-la-menopause-THS; 2005.
  30. Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrino F. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol. 2005;96:95–108
  31. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107:103–111
  32. Collins JA, Blake JM, Crosignani PG. Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update. 2005;11:545–560
  33. Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol. 2008;26:1260–1268
  34. Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA. 2003;289:3254–3263
  35. Lee S, Kolonel L, Wilkens L, Wan P, Henderson B, Pike M. Postmenopausal hormone therapy and breast cancer risk: the Multiethnic Cohort. Int J Cancer. 2006;118:1285–1291
  36. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res. 2007;9:R28
  37. Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Coates RJ, et al. Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer. 2002;95:2455–2464
  38. Chen CL, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA. 2002;287:734–741
  39. Newcomer LM, Newcomb PA, Potter JD, Yasui Y, Trentham-Dietz A, Storer BE, et al. Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States). Cancer Causes Control. 2003;14:225–233
  40. Rosenberg LU, Granath F, Dickman PW, Einarsdottir K, Wedren S, Persson I, et al. Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study. Breast Cancer Res. 2008;10:R78
  41. Sener SF, Winchester DJ, Winchester DP, Du H, Barrera E, Bilimoria M, et al. The effects of hormone replacement therapy on postmenopausal breast cancer biology and survival. Am J Surg. 2009;197:403–407
  42. Ringa V, Fournier A. Did the decrease in use of menopausal hormone therapy induce a decrease in the incidence of breast cancer in France (and elsewhere)?. Rev Epidemiol Sante Publique. 2008;56:297–301

PII: S1877-7821(10)00040-8

doi: 10.1016/j.canep.2010.03.007

Cancer Epidemiology
Volume 34, Issue 3 , Pages 238-243 , June 2010

Article Tools

* Image Usage & Resolution